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BACKGROUND. Expression of the a-methylacyl-CoA racemase (AMACR) gene has been
established as a sensitive and specific biomarker for the diagnosis of prostate cancer. An initial
study has also suggested that the risk of familial (but not sporadic) prostate cancer may be
associated with germline variation in the AMACR gene.
METHODS. In a study of brothers discordant for the diagnosis of prostate cancer (including
449 affected and 394 unaffectedmen) from 332 familial and early-onset prostate cancer families,
we used conditional logistic regression and family-based association tests to investigate the
association between prostate cancer and five single nucleotide polymorphisms (SNPs) tagging
common haplotype variation within the coding and regulatory regions of AMACR.
RESULTS. The strongest evidence for prostate cancer associationwas for SNP rs3195676, with
an estimated odds ratio of 0.58 (95% confidence interval¼ 0.38–0.90; P¼ 0.01 for a recessive
model). This non-synonymous SNP (nsSNP) results in a methionine-to-valine substitution at
codon 9 (M9V) in exon 2 of the AMACR gene. Three additional nsSNPs showed suggestive
evidence for prostate cancer association (P 0.10).
CONCLUSIONS. Our results confirm an initial report of association between the AMACR
gene and the risk of familial prostate cancer. These findings emphasize the value of studying
early-onset and familial prostate cancer when attempting to identify genetic variation
associated with prostate cancer. Prostate 67: 1507–1513, 2007. # 2007 Wiley-Liss, Inc.
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INTRODUCTION
The a-methylacyl-CoA racemase (AMACR) gene is
normally expressed in the prostate [1,2] as well as a
number of other tissues, including the liver, kidney,
salivary glands, gallbladder, and colon [3,4]. It is
also over-expressed in a variety of carcinomas [5,6]. In
particular, because of the consistent over-expression of
AMACR in prostate cancer in comparison to normal
prostate cells [4,7–9], AMACR has become a standard
clinical biomarker for the diagnosis of prostate cancer
with sensitivity and specificity ranging from 82% to
100% and 79% to 100%, respectively [10]. Still, the
influence ofAMACR on prostate cancer initiation and/
or progression remains unclear.
The AMACR protein is primarily found within
peroxisomes and mitochondria, where it catalyzes a
critical step in the metabolism of branch-chained fatty
acids [11], and a complete deficiency of this enzyme
has been implicated in adult-onset sensory motor
neuropathy [12]. The AMACR gene is located on
chromosome 5p13.3 in a region near a number of
prostate cancer linkage signals [13–15]. In particular, a
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recent genome-wide scan based on 175 brother-
pairs recruited through the University of Michigan
Prostate Cancer Genetics Project (PCGP) demonstrated
significant linkage between markers on 5p13-q11
and prostate cancer aggressiveness, as measured by
Gleason score [16]. These studies suggest that this
region of the genome may harbor sequence variation
associatedwithprostate cancer risk and extent of tumor
differentiation, a predictor for prognosis.
An initial study suggested that single nucleotide
polymorphisms (SNPs) in AMACR were associated
with familial but not sporadic prostate cancer [17].
Two subsequent studies [18] (http://cgems.cancer.gov)
failed to identify a significant association between
the AMACR gene and sporadic prostate cancer.
However, there have been no other association studies
of AMACR in familial prostate cancer. Taking a
gene-based replication approach, we comprehensively
re-sequenced the exons andpromoter region ofAMACR
and selected a set of haplotype-tagging SNPs (htSNPs).
We then genotyped these htSNPs and assessed their
association with prostate cancer in a family-based
association study of 332 families from the PCGP [19],




The PCGP is a large, ongoing family-based study
designed to map and clone genes predisposing to
inherited forms of prostate cancer. Enrollment into
the PCGP is restricted to (1) families with two or
more living members with prostate cancer in a first-
or second-degree relationship or (2) men diagnosed
with prostate cancer at 55 years of age without a
family history of the disease. All participants are asked
to provide a blood sample, extended family history
information, and access to medical records. For the
present investigation, we identified 349 families in
which we had DNA from at least one pair of brothers
discordant for prostate cancer. The majority of these
discordant sibling pairs (DSPs) were selected from a
single generation to mitigate potential cohort effects.
We also preferentially enrolled the oldest available
unaffected brother from each family to maximize the
probability that unaffected men were truly unaffected
and not simply unaffected by virtue of being younger
than their affected brother(s). Additional male siblings
as well as multiple sibships from the same family were
included if DNA was available.
The majority of PCGP families were recruited
directly from the University of Michigan Compre-
hensive Cancer Center. Other sources included direct
patient or physician referrals. Diagnosis of prostate
cancer was confirmed by review of pathology reports
ormedical records, and age at diagnosiswas calculated
from the date of the first biopsy positive for prostate
cancer. Cases were classified as clinically aggressive
if they met at least one of the following criteria:
(1) pathologic Gleason sum >7, (2) pathologic stage
T3b (pT3b) tumor (indicating seminal vesicle involve-
ment) or pT4 orN1 (positive regional lymph nodes), (3)
pathologic Gleason sum of 7 and a positive margin, or
(4) pre-operative serumprostate-specific antigen (PSA)
value >15 ng/ml, or a biopsy Gleason score >7, or a
serum PSA level >10 ng/ml, and a biopsy Gleason
score>6. Based on data from D’Amico et al., [20] these
criteria were developed by the Southwest Oncology
Group (protocol 9921) to identify men at intermediate
to high risk of clinical recurrence after primary therapy.
Disease status of the unaffected brothers was con-
firmed through serum PSA testing whenever possible.
The majority of the 349 families were non-Hispanic
white (n¼ 332), although 15 African American and 2
Asian families were also recruited. All of the follow-
ing results, however, were restricted to the sample of
332 non-Hispanic white families. This decision was
supported by an analysis of HapMap data, which
revealed substantial allele frequency differences and
dissimilar linkage disequilibrium (LD) patterns in the
AMACR gene region between African, Asian, and
European samples. The Institutional Review Board at
the University of Michigan Medical School approved
all aspects of the protocol, and all participants gave
written informed consent, including permission to
release their medical records.
Resequencing andHaplotype-Tagging SNPSelection
Genomic DNAwas isolated fromwhole blood using
the Puregene kit (Gentra Systems Inc., Minneapolis,
MN). We sequenced all five exons, the intron/
exon boundaries, the promoter region, and the 30UTR
of AMACR in 20 unrelated men without prostate
cancer. A total of 12 SNPswith aminor allele frequency
0.05 were discovered. Using these data, we applied
the dynamic programming algorithm proposed by
Zhang et al. [21] and implemented in the program
HapBlock [22] (version 3.0) to partition this region into
blocks and select a maximally informative set of SNPs
based on common haplotypes. Specifically, we defined
common haplotypes as those having frequency 0.05
(i.e., haplotypes inferred to be present at least two times
among40 chromosomes), andwedefined a consecutive
set of SNPs as a block if common haplotypes accounted
for at least 90% of all predicted haplotypes. We then
determined htSNPs as the minimum set of SNPs that
distinguished all common haplotypes inferred within
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each block. Based on these criteria, the 12 SNPs
clustered into two, non-overlapping blocks of limit-
ed haplotype diversity, and 5 htSNPs (rs3195676,
rs2287939, rs34677, and rs2278008 in the first block
and rs15612 in the second block) distinguished 92.5%
and 100% of all haplotypes inferred within the first
and second blocks, respectively.
htSNPGenotyping
We genotyped all five htSNPs with TaqMan SNP-
Genotyping Assays (Applied Biosystems, Foster City,
CA), and we used the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) to distinguish
SNP alleles as previously described [19]. Details of
specific SNP assays are available from the authors on
request. On average, we achieved a genotyping call
rate of 99.35% with call rates 98.43% for each SNP.
We sequenced SNPs that were undetermined by
the assay for a final genotyping call rate of 100%. A
subset of samples was also duplicated and verified by
either TaqMan SNP genotyping or direct sequencing.
We observed one discrepancy among 459 duplicate
genotype pairs by TaqMan SNP genotyping and one
discrepancy among 154 duplicate genotype pairs by
direct sequencing, yielding genotyping reproducibility
rates of 99.8% and 99.4%, respectively.
DataAnalysisMethods
The observed genotype distributions were tested
for departures fromHardy–Weinberg equilibrium in a
subset of unaffected, unrelated men by selecting
the oldest unaffected man from each family. Two-
SNP haplotype frequencies were estimated using the
expectation-maximization algorithm and were used to
calculate the LDmeasure r2 between each pair of SNPs.
We used conditional logistic regression with family
as the stratification variable and a robust variance
estimate that incorporates familial correlations due to
potential linkage [23] to estimate odds ratios (OR’s) and
95% confidence intervals (CI’s) for the association
between genotypes and prostate cancer. In parallel,
we used the family-based association test (FBAT)
program (version 1.5.5) to test for association between
genotypes and prostate cancer. FBATs are a class of
generalized score statistics that utilize within- and
between-family marker-inheritance patterns to test
for association [24,25]. We employed the empirical
variance function in FBAT, which is a valid test of the
null hypothesis of no association in the presence of
linkage. To maximize power, we analyzed the com-
bined sample of affected and unaffected men using the
offset option. We also carried out affecteds-only
analyses to allow for the possibility of misclassification
of unaffected men (e.g., via reduced penetrance). Both
conditional logistic regression analyses and FBATs
were carried out assuming additive, dominant, and
recessive genetic models. For conditional logistic
regression and affecteds-only FBATs, we also examin-
ed a general (2 degrees of freedom) genotype model.
Predetermined stratified analyseswere also performed
to explore the relationship between genotypes and
prostate cancer, stratifying on clinically advanced
prostate cancer, age at diagnosis (<50years), or number
of confirmed cases of prostate cancer within a family
(3).
To assess the association of haplotypeswith prostate
cancer, we divided each of the htSNPs by block
and examined the four-SNP haplotype corresponding
to the first block and the five-SNP haplotype from
both blocks. All haplotypes were analyzed using the
haplotype FBAT (HBAT)method [26].We jointly tested
all four- and five-SNP haplotypes for association with
prostate cancer (i.e., a global test). We also tested each
individual haplotype for association with prostate
cancer, assuming additive, dominant, and recessive
genetic models. As described above for FBAT, we used
the empirical variance option to account for prostate
cancer linkage to this region and the offset option to
weight the contribution of unaffected and affected
subjects.
All statistical tests were two-sided, and P-values
<0.05 were considered statistically significant. Condi-
tional logistic regression was conducted using version
8.2 of the SAS-programming language (SAS Institute,
Cary, NC). All remaining analyses (except where
noted above) were conducted using the R language
(version 2.1.1).
RESULTS
For this investigation, we identified 332 families
with at least onediscordant siblingpair (DSP), resulting
in a total of 530 DSPs. Of the 332 families, 322 included
only the index case and one or more of his brothers.
The remaining 10 families included additional DSPs
unrelated to the index case as a brother (e.g., a pair
of DSPs related as first cousins). Approximately 32%,
38%, and 30% of families included one, two, and
three or more men with prostate cancer, respectively.
The total sample consisted of 817 men (449 affected
and 394 unaffected men). The clinical characteristics of
men with prostate cancer are shown in Table I.
The median age at diagnosis was 55 years (inter-
quartile range¼ 50–63 years). At the time of consent,
the median age of unaffected men was also 56 years
(inter-quartile range¼ 50–63 years). Over 76% of
unaffected men reported their most recent PSA testing
results and/or had their PSA values confirmed by
medical record review, and >94% of them reported
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and/or had a PSA level <4.0 mg/dl or normal. At
the time of consent, unaffected men were significantly
older than their affected brothers were at their time of
diagnosis (P< 0.0001 for paired t-test of within family
means), with a mean age difference of 3 years.
As described above, the five htSNPswere situated in
two haplotype blocks. The first block contained four
nsSNPs and the second block contained a single SNP
located in the 30 UTRofAMACR (Table II). In a subset of
332 unaffected, unrelated men, the observed genotype
data for each htSNP were consistent with Hardy–
Weinberg equilibrium. Minor allele frequencies for all
five htSNPs are presented in Table II for both affected
and unaffected men.
Results from family-based association analyses
and conditional logistic regression are presented in
Table III. Our strongest evidence for prostate cancer
association was for SNP rs3195676, which results in a
methionine-to-valine substitution at codon 9 (M9V) in
exon 2 of the AMACR gene. The minor allele of
rs3195676 was preferentially transmitted to unaffected
men (z¼2.55; P-value¼ 0.01 for a recessive model),
with an odds ratio of 0.58 (95% CI 0.38–0.90;
P-value¼ 0.01). Similarly, but based on the analysis
of affected men only, the minor allele of SNP rs34677
was preferentially transmitted to unaffected men
(z¼2.03; P-value¼ 0.04 for a recessive model). SNP
rs34677 results in a glutamine-to-histadine substitution
in codon 239 (Q239H) in exon 4 of AMACR. We found
no significant evidence of prostate cancer association
with the remaining SNPs (i.e., rs2287939, rs2278008,
and rs15612).
As described above, analyses were repeated after
stratifying on age at diagnosis (<50 years), clinically
aggressive prostate cancer, and number of confirmed
cases of prostate cancer within a family (3). After
stratification, theminor allele of SNP rs15612was over-
transmitted to affected men in the subset of families in
which affected men were diagnosed with prostate
cancer at <50 years of age (z¼ 2.25; P¼ 0.02 for a
recessive model), with an odds ratio of 4.00 (95%
CI¼ 1.01–15.48; P¼ 0.05). In contrast, the minor allele
of rs15612 was under-transmitted to affected men
diagnosed at  50 years of age (z¼2.12; P¼ 0.03 for
a recessive model) with an odds ratio of 0.48 (95%
CI¼ 0.22–1.05;P¼ 0.07). This potential interactionmay
explain the non-significant result for rs15612 in the
unstratified analysis. None of the other subset results
for rs15612 or the four nsSNPs were significant.
Similarly, haplotype analyses did not reveal a parti-
cular haplotype(s) that was a better predictor of
prostate cancer risk than the individual SNPs.
DISCUSSION
By studying families enriched for early-onset
and familial prostate cancer, we have confirmed the
prostate cancer association with the AMACR gene first
reported by Zheng et al. [17] in their case-control
sample of familial prostate cancer. Estimates of the
odds ratios for the nsSNPs that were tested in common
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TABLE I. Characteristics of Men With Prostate Cancer
(n¼ 449)
Trait No.a (%)
Age at diagnosis (years)b 55 (50–63)
Pre-diagnosis PSA (mg/dl)b 5.7 (4.2–9.3)
Surgeryc (% yes) 343 (77%)
Stage:
Localized 335 (78%)






Clinically aggressive CaP (%) 156 (35%)
aNote that column subtotals do not sum to 449 due to missing
data.
bMedian and (interquartile range) are reported.
cNumber and (percentage) of men with prostate cancer who
underwent a radical prostatectomy.











rs3195676 Exon 1 M9V T>C 0.46 0.48
rs2287939 Exon 4 S201L G>A 0.30 0.30
rs34677 Exon 4 Q239H C>A 0.13 0.14
rs2278008 Exon 5 K277E T>C 0.26 0.26
rs15612 30 UTR — C>T 0.32 0.31
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between the current and initial study showed a
consistent protective effect for prostate cancer
(Table IV). Although results from the current study
were not all statistically significant, none were signi-
ficantly different from the initial study. The lack of
significant findings in studies of sporadic prostate
cancer, including two additional, independent case-
control studies of sporadic prostate cancer [18] (http://
cgems.cancer.gov), may be related to increased genetic
heterogeneity in these samples, which could lead to a
decrease in the power to detect small, marginal effects.
Because nsSNPs directly alter the protein sequence,
it is possible that they may have a deleterious effect.
However, no studies to date have investigated the
impact of amino acid substitutions on the stability
and/or function of the AMACR protein. To indirectly
investigate this impact, we performed a sorting
intolerant from tolerant (SIFT) analysis [27,28]. This
bioinformatic tool predicts the influence of an amino
acid substitution on the integrity of the protein through
cross-species conservation, where highly conserved
amino acids are more likely to be intolerant to
substitutions in comparison to amino acids that are
not conserved. By this method, the minor alleles of
rs3195676 (M9V) and rs34677 (Q239H) were both
predicted to be ‘‘intolerant’’ substitutions, suggesting
that these SNPs may damage the protein. If the over-
expression of AMACR commonly seen in prostate
tumors plays a direct role in tumorigenesis (i.e., is not
just a biomarker of disease), substitutions that damage
the wild-type protein could have a protective effect
with regard to prostate cancer risk. Consistentwith this
hypothesis, recessive carriers of the minor allele for
each of the two SIFT-predicted intolerant SNPs had a
significant decrease in their risk of prostate cancer.
In accordance with our findings, there is biological
evidence to suggest that AMACR expression plays a
role in the early stages of prostate tumor development.
For instance, several studies suggest that AMACR is
over-expressed in high-grade prostatic intraepithelial
neoplasia [1,6,10], a precursor lesion for prostate cancer
[29]. Further, Zha et al. [30] have shown that inhibition
of AMACR in a prostate cancer cell line significantly
reduces its proliferation in comparison to uninhibited
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TABLE III. Association Results FromConditional Logistic Regression and Family-BasedAssociationTests (FBATs)
SNP name Genotypea
Discordant sib pairs (DSPs) Affected men
Affected and
unaffected men
OR 95% CI P-value Nb Z P-value Nb Z P-value
rs3195676 TT or TC vs. CC 0.58 0.38,0.90 0.01 97 2.70 <0.01 98 2.55 0.01
rs2287939 GG or GA vs. AA 0.53 0.25,1.08 0.08 41 1.22 0.22 42 1.36 0.17
rs34677 CC or CA vs. AA 0.34 0.10,1.21 0.10 13 2.03 0.04 13 1.79 0.07
rs2278008 TT or TC vs. CC 0.48 0.22,1.05 0.07 36 1.87 0.06 37 1.68 0.09
rs15612 CC or CT vs.TT 0.85 0.45,1.60 0.60 50 1.09 0.27 50 0.67 0.50
Results are based on 332 families (517 and 530 DSPs for conditional logistic regression and FBAT analyses, respectively).
aFirst two genotypes represent the referent group.
bNumber of informative families.
TABLE IV. Comparison of theOdds Ratios (ORs) for AMACRnsSNPsTested in theUniversityof Michigan (UM)Discordant
Sibling Pair Studyandthe JohnsHopkinsUniversity (JHU) Familial and Sporadic Case-Control Studies*
SNP name Genotypea
UM JHU
Familial and/or early onset Familial Sporadic
OR 95% CI ORb 95% CI ORb 95% CI
rs3195676 TT or TC vs. CC 0.58 0.38,0.90 0.47 0.26,0.85 0.73 0.46,1.15
rs2287939 GG or GA vs. AA 0.53 0.25,1.08 0.29 0.10,0.90 0.81 0.40,1.62
rs34677 CC or CA vs. AA 0.34 0.10,1.21 0.23 0.03,1.96 0.85 0.27,2.67
rs2278008 TT or TC vs. CC 0.48 0.22,1.05 0.37 0.13,1.01 0.65 0.32,1.32
*Zheng et al. 2002.
aFirst two genotypes represent the referent group.
bUn-adjusted odds ratio from logistic regression.
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cells and that this antiproliferative effect is androgen
independent. In addition, a recent study has demon-
strated that the re-introduction of glucocorticoid
receptor in a prostate cancer cell line leads to reduced
AMACR expression, reduced cell proliferation, and
loss of anchorage-independent growth [31].
In our primary unstratified analyses, only SNP
rs3195676 achieved statistical significance after a
Bonferroni correction for multiple comparisons. While
the SIFT analysis suggests that this nsSNPmay directly
influence prostate cancer risk through its impact on the
AMACR protein, we cannot rule out the possibility
that the association could be due to LD with other
genetic variants. For example, data from the HapMap
sample of 60 unrelated Caucasian individuals from a
Utah population with northern and western European
ancestry [32] (March 2007 release—build #22) suggest
that rs3195676 is in high LD (r2 0.8) with five other
SNPs on chromosome 5, all within the AMACR gene.
These five SNPs include three intronic SNPs and
two nsSNPs. Although these SNPswere not genotyped
as part of our association study, the two nsSNPs
(rs1094112 and rs1094110) were identified in our
resequencing data and were both in perfect pair-wise
LD (r2¼ 1) with rs3195676. Of note, nsSNP rs1094112,
which encodes an aspartate-to-glycine amino acid
substitution in codon 175 of AMACR, was also typed
byZheng et al. [17] anddemonstrated stronger prostate
cancer association in combination with rs3195676 as a
two-SNP haplotype relative to the individual SNPs.
Also of note, recent three-dimensional structural data
suggest that the substitution encodedby rs1094112may
directly impact the stability of the AMACR protein
backbone [33]. Still, experimental studies are needed
to evaluate both the marginal and joint functional
consequences of these nsSNPs.
In conclusion, we have replicated the initial report
[17] of associationbetween theAMACR gene and risk of
familial prostate cancer. In both the original and
current study, individuals with an inherited pre-
disposition to prostate cancer were selected, namely,
by virtue of having a family history of prostate cancer
and/or an early age of onset. These individuals may
have added value in the context of prostate cancer
association studies since they are likely to be more
enriched for a genetic form of the disease than sporadic
cases. Our study also emphasizes the broader impor-
tance of carefully considering the detailed sampling
characteristics of the original studywhen attempting to
replicate genetic association findings.
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